A5066832095- Blood Pressure and Hypertension Studies
- Heart Rate Variability and Autonomic Control
- Cardiovascular and exercise physiology
- Heart Failure Treatment and Management
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac Health and Mental Health
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Sodium Intake and Health
- Cardiovascular Health and Disease Prevention
- Health Systems, Economic Evaluations, Quality of Life
- Hemodynamic Monitoring and Therapy
- RNA Interference and Gene Delivery
- Hormonal Regulation and Hypertension
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac, Anesthesia and Surgical Outcomes
- Renal and Vascular Pathologies
- Neuroscience of respiration and sleep
- Advanced biosensing and bioanalysis techniques
- Healthcare Systems and Practices
- Pharmaceutical industry and healthcare
- Medication Adherence and Compliance
Princess Grace Hospital Centre
2019-2025
Manipal Hospital
2025
Laboratoire National de Santé
2025
Fondation de France
2024
Radiance Technologies (United States)
2022-2023
Centre National de la Recherche Scientifique
2012-2023
French Clinical Research Infrastructure Network
2017-2022
Centre d'Anthropobiologie et de Génomique de Toulouse
2021-2022
The Princess Grace Hospital
2022
Hôpital Avicenne
2021
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering...
This ESH Position Paper 2021 with updated proposed recommendations was deemed necessary after the publication of a set new pivotal sham-controlled randomized clinical trials (RCTs), which provided important information about efficacy and safety endovascular device-based renal denervation (RDN) for hypertension treatment. RDN is effective in reducing or interrupting sympathetic signals to kidneys decreasing whole body activity. Five independent, fully completed, RCTs provide conclusive...
Since the publication of 2018 European Society Cardiology/European Hypertension (ESC/ESH) Guidelines for Management Arterial Hypertension, several high-quality studies, including randomised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both blood pressure (BP)-lowering efficacy and safety radiofrequency ultrasound RDN in a broad range patients with hypertension, resistant hypertension. A clinical consensus document by ESC Council Association...
Renal denervation (RDN) has demonstrated clinically relevant reductions in blood pressure (BP) among individuals with uncontrolled hypertension despite lifestyle intervention and medications. The safety effectiveness of alcohol-mediated RDN have not been formally studied this indication.
Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI).To perform sequential analysis clinical genetic factors associated with definite early thrombosis.Case-control study conducted in 10 centers France between January 2007 May 2010 among 123 patients undergoing PCI who had DNA samples available, matched on age sex 246 thrombosis-free controls.Accuracy prediction by 23 variants.Among the variants...
Approximately 8–18% of all patients with high blood pressure (BP) are apparently resistant to drug treatment.1,2 In this situation, new strategies help reduce BP urgently needed but the complex pathophysiology hypertension makes search difficult. Not surprisingly in context, latest non-drug treatment which triggered controversy is catheter-based renal denervation (RDN).3,4 The method uses radiofrequency energy, or alternatively ultrasound chemical denervation, disrupt nerves within artery...
Adipose tissue secretes a variety of bioactive factors, which can regulate cardiomyocyte hypertrophy via reactive oxygen species (ROS). In the present study we investigated whether apelin affects ROS‐dependent cardiac hypertrophy. cardiomyocytes inhibited hypertrophic response to 5‐HT and oxidative stress induced by 5‐HT‐ or H 2 O in dose‐dependent manner. These effects were concomitant increase mRNA expression activity catalase. Chronic treatment mice with attenuated...
Intra-individual heterogeneity of cardiac exposure is an issue in breast cancer (BC) radiotherapy that was poorly considered previous cardiotoxicity studies mainly based on mean heart dose (MHD). This dosimetric study analyzes the distribution individually-determined radiation doses to and its substructures including coronary arteries evaluate whether MHD a relevant surrogate parameter for these substructures.Data were collected from BACCARAT prospective included left or right unilateral BC...
Intracranial pressure (ICP) is the within cranium. ICP rise compresses brain vessels and reduces cerebral blood delivery. Massive leads to ischemia, but it also known produce hypertension, bradycardia respiratory irregularities due a sympatho-adrenal mechanism termed Cushing response. One still unresolved question whether response non-synaptic acute brainstem ischemic or part of larger physiological reflex for arterial control homeostasis regulation. We hypothesize that changes in modulates...
Hyperactivity of the renin–angiotensin–aldosterone system through angiotensin II (Ang II)/Ang type 1 receptor (AT1-R) axis constitutes a hallmark hypertension. Recent findings indicate that only subset AT1-R signaling pathways is cardiodeleterious, and their selective inhibition by biased ligands promotes therapeutic benefit. To date, synthetic have been described, whether natural peptides exhibit functional selectivity at remains unknown. In this study, we systematically determined efficacy...
The aim of this multicenter, open-label trial was to evaluate the safety and efficacy alcohol-mediated renal denervation using a novel catheter system (the Peregrine System Infusion Catheter) for infusion dehydrated alcohol as neurolytic agent into periarterial space. number hypertensive patients with uncontrolled blood pressure (BP) remains unacceptably high. sympathetic nervous has been identified an attractive therapeutic target. Forty-five hypertension on ≥3 antihypertensive medications...